Department of Urology, Medway Maritime Hospital, Gillingham, United Kingdom.
Urology. 2013 Jan;81(1):98-103. doi: 10.1016/j.urology.2012.08.037. Epub 2012 Oct 24.
To determine the efficacy and safety of tramadol in the treatment of premature ejaculation (PE) by systematically reviewing the results of randomized controlled trials.
All studies evaluating the efficacy of tramadol for the treatment of PE published in peer reviewed medical journals between 2006 and March 2012 were identified by searching for the keywords "premature ejaculation" and "tramadol" in the PubMed database. Only randomized controlled trials published in the English language were included.
A total of 5 articles, comprising 823 patients, met the inclusion criteria for further analysis. Overall, tramadol on-demand results in a significant improvement in mean intravaginal ejaculatory latency time and symptom scores compared with placebo and in an improvement in partner sexual satisfaction scores. The rate of short-term adverse effects is low.
Tramadol is an effective treatment for patients with PE and represents a promising alternative to the currently used oral pharmacologic agents. Longer-term safety studies, and those comparing tramadol with the selective serotonin receptor inhibitors, are essential to determine the place of tramadol in the treatment of this distressing condition.
通过系统评价随机对照试验的结果,确定曲马多治疗早泄(PE)的疗效和安全性。
检索 2006 年至 2012 年 3 月期间在同行评审医学期刊上发表的评估曲马多治疗 PE 疗效的所有研究,使用的关键词为“早泄”和“曲马多”。仅纳入发表于英文期刊的随机对照试验。
共有 5 篇文章,包含 823 例患者,符合进一步分析的纳入标准。总体而言,按需使用曲马多与安慰剂相比,可显著延长阴道内射精潜伏期和症状评分,改善伴侣性满意度评分。短期不良反应发生率低。
曲马多是治疗早泄患者的有效方法,为目前使用的口服药物治疗方法提供了一种有前景的替代方法。为确定曲马多在治疗这种令人痛苦的疾病中的地位,还需要进行更长期的安全性研究,并比较曲马多与选择性 5-羟色胺再摄取抑制剂的疗效。